

Markus Moehler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9130715/publications.pdf>

Version: 2024-02-01

58
papers

8,338
citations

172386
29
h-index

138417
58
g-index

61
all docs

61
docs citations

61
times ranked

8687
citing authors

#	ARTICLE	IF	CITATIONS
1	Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe. <i>European Journal of Cancer</i> , 2022, 164, 18-29.	1.3	27
2	A population-based study in resected esophageal or gastroesophageal junction cancer aligned with CheckMate 577. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210754.	1.4	4
3	Immunotherapy in Gastric Cancer. <i>Current Oncology</i> , 2022, 29, 1559-1574.	0.9	65
4	Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (<scp>LICC</scp>, <scp>CELIM</scp>, <scp>FIRE</scp>â€³). <i>International Journal of Cancer</i> , 2022, 150, 1341-1349.	2.3	6
5	FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial. <i>British Journal of Cancer</i> , 2021, 124, 587-594.	2.9	79
6	Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100. <i>Journal of Clinical Oncology</i> , 2021, 39, 966-977.	0.8	122
7	First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2021, 398, 27-40.	6.3	1,237
8	The Addition of Transarterial Chemoembolization to Palliative Chemotherapy Extends Survival in Intrahepatic Cholangiocarcinoma. <i>Journal of Clinical Medicine</i> , 2021, 10, 2732.	1.0	8
9	Virotherapy in Germanyâ€”Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies. <i>Viruses</i> , 2021, 13, 1420.	1.5	19
10	CXCR4 and hif-1â€± as prognostic molecular markers for stage 3 colon cancer patients: post hoc analysis of the randomized, multicenter phase 3 PETACC-2 trial dataset. <i>Acta OncolÃ³gica</i> , 2021, 60, 1543-1547.	0.8	1
11	Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin. <i>Journal of Clinical Oncology</i> , 2021, 39, 4009-4019.	0.8	45
12	Gastric cancer in autoimmune gastritis: A caseâ€”control study from the German centers of the staR project on gastric cancer research. <i>United European Gastroenterology Journal</i> , 2020, 8, 175-184.	1.6	30
13	Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC). <i>Onc Immunology</i> , 2020, 9, 1806680.	2.1	11
14	Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER). <i>Annals of Oncology</i> , 2020, 31, 228-235.	0.6	60
15	Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer. <i>Journal of Hepatology</i> , 2020, 73, 1109-1117.	1.8	25
16	Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State. <i>Targeted Oncology</i> , 2019, 14, 505-525.	1.7	40
17	Rational Combination of Parvovirus H1 With CTLA-4 and PD-1 Checkpoint Inhibitors Dampens the Tumor Induced Immune Silencing. <i>Frontiers in Oncology</i> , 2019, 9, 425.	1.3	13
18	Loss of LLGL1 Expression Correlates with Diffuse Gastric Cancer and Distant Peritoneal Metastases. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2019, 2019, 1-12.	0.8	4

#	ARTICLE	IF	CITATIONS
19	Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. <i>Lancet, The</i> , 2019, 393, 1948-1957.	6.3	1,494
20	Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naïve patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program. <i>BMC Cancer</i> , 2019, 19, 55.	1.1	24
21	VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or Tj ETQq1 1 0.784314 rgBT /Over	1.3	33
22	Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/CAO STO-0801). <i>European Journal of Cancer</i> , 2018, 93, 119-126.	1.3	33
23	Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE/AIO KRK0306 trial. <i>International Journal of Cancer</i> , 2018, 142, 1047-1055.	2.3	12
24	Evidence for <i>PTGER4</i> , <i>PSCA</i> and <i>MBOAT7</i> as risk genes for gastric cancer on the genome and transcriptome level. <i>Cancer Medicine</i> , 2018, 7, 5057-5065.	1.3	22
25	Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 130, 13-26.	2.0	34
26	Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives. <i>Cancer Treatment Reviews</i> , 2018, 66, 104-113.	3.4	78
27	Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: a randomized placebo-controlled phase II study (EORTC 40071). <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 733-739.	1.1	13
28	Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. <i>Lancet, The</i> , 2018, 392, 123-133.	6.3	984
29	Molecular landscape of esophageal cancer: implications for early detection and personalized therapy. <i>Annals of the New York Academy of Sciences</i> , 2018, 1434, 342-359.	1.8	56
30	Phase I study of orally administered S-1 in combination with epirubicin and oxaliplatin in patients with advanced solid tumors and chemotherapy-naïve advanced or metastatic esophagogastric cancer. <i>Gastric Cancer</i> , 2017, 20, 358-367.	2.7	4
31	Current management of liver metastases from gastric cancer: what is common practice? New challenge of EORTC and JCOG. <i>Gastric Cancer</i> , 2017, 20, 904-912.	2.7	33
32	Chemotherapy for advanced gastric cancer. <i>The Cochrane Library</i> , 2017, 2017, CD004064.	1.5	662
33	Virotherapy Research in Germany: From Engineering to Translation. <i>Human Gene Therapy</i> , 2017, 28, 800-819.	1.4	19
34	Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5671-5678.	3.2	121
35	Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2389-2401.	1.0	36
36	Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program. <i>BMC Cancer</i> , 2016, 16, 699.	1.1	54

#	ARTICLE	IF	CITATIONS
37	Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives. <i>European Journal of Cancer</i> , 2016, 59, 160-170.	1.3	78
38	The Barrett's-associated variants at <i>GDF7</i> and <i>TBX5</i> also increase esophageal adenocarcinoma risk. <i>Cancer Medicine</i> , 2016, 5, 888-891.	1.3	21
39	Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints. <i>Targeted Oncology</i> , 2016, 11, 469-477.	1.7	34
40	Supportive evidence for <i>FOXP1</i> , <i>BARX1</i> , and <i>FOXF1</i> as genetic risk loci for the development of esophageal adenocarcinoma. <i>Cancer Medicine</i> , 2015, 4, 1700-1704.	1.3	26
41	Inclusion of targeted therapies in the standard of care for metastatic colorectal cancer patients in a German cancer center: the more the better?!. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 515-522.	1.2	10
42	International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus. <i>Gastric Cancer</i> , 2015, 18, 550-563.	2.7	79
43	Moguntinones' New Selective Inhibitors for the Treatment of Human Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 1399-1409.	1.9	5
44	Oncolytic Virotherapy as Emerging Immunotherapeutic Modality: Potential of Parvovirus H-1. <i>Frontiers in Oncology</i> , 2014, 4, 92.	1.3	22
45	Erythropoietin treatment in chemotherapy-induced anemia in previously untreated advanced esophagogastric cancer patients. <i>International Journal of Clinical Oncology</i> , 2014, 19, 288-296.	1.0	11
46	FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1065-1075.	5.1	1,479
47	VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). <i>BMC Cancer</i> , 2014, 14, 476.	1.1	8
48	Activation of the human immune system via toll-like receptors by the oncolytic parvovirus H-1. <i>International Journal of Cancer</i> , 2013, 132, 2548-2556.	2.3	32
49	Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 490-499.	5.1	740
50	Influence of the oncolytic parvovirus H-1, CTLA-4 antibody tremelimumab and cytostatic drugs on the human immune system in a human in vitro model of colorectal cancer cells. <i>OncoTargets and Therapy</i> , 2013, 6, 1119.	1.0	16
51	VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab. <i>World Journal of Gastroenterology</i> , 2008, 14, 4156.	1.4	36
52	Multimodal treatment of gastric cancer. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2007, 21, 965-981.	1.0	35
53	(Neo)adjuvant Strategies of Advanced Gastric Carcinoma: Time for a Change?. <i>Digestive Diseases</i> , 2004, 22, 345-350.	0.8	18
54	Oncolytic parvovirus H1 induces release of heat-shock protein HSP72 in susceptible human tumor cells but may not affect primary immune cells. <i>Cancer Gene Therapy</i> , 2003, 10, 477-480.	2.2	49

#	ARTICLE	IF	CITATIONS
55	Safety and efficacy of outpatient treatment with CPT-11 plus bolus folinic acid/5-fluorouracil as first-line chemotherapy for metastatic colorectal cancer. <i>Anti-Cancer Drugs</i> , 2003, 14, 79-85.	0.7	14
56	Weekly treatment with irinotecan, folinic acid and infusional 5-fluorouracil (ILF) in patients with advanced gastric cancer. <i>Anti-Cancer Drugs</i> , 2003, 14, 645-650.	0.7	17
57	Comparison of a 48-Hour Infusion of 5-Fluorouracil without Folinic Acid with 24-Hour Folinic Acid/5-Fluorouracil in Patients with Metastatic Colorectal Cancer Refractory to Bolus Folinic Acid/5-Fluorouracil. <i>Chemotherapy</i> , 2003, 49, 85-89.	0.8	8
58	Effective infection, apoptotic cell killing and gene transfer of human hepatoma cells but not primary hepatocytes by parvovirus H1 and derived vectors. <i>Cancer Gene Therapy</i> , 2001, 8, 158-167.	2.2	68